Head to head
PROCEPT BioRobotics vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: PRCT · ABT
PRCT
PROCEPT BioRobotics
17.58-1.84%
1-year price shape — -48% over the period
Quant Rating D · 51/100
vs
ABT
Abbott Laboratories
97.43-1.32%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories has done best over the past year (-24%); Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| PRCT | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 17.58 | 97.43 |
| Change today | -1.84% | -1.32% |
| 1-year return | -48.3% | -24.1% |
| Market cap | $1.01B | $168.58B |
| 52-week range | 16.67 – 38.11 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -9.02 | 31.53 |
| P/E percentile, own 5-yr range | 91st | 62nd |
| P/B | 2.96 | 3.30 |
| Dividend yield | 0.00% | 2.50% |
| Profitability & growth | ||
| EPS (TTM) | -1.72 | 3.72 |
| Net profit (TTM) | $-98.51M | $6.44B |
| Revenue (TTM) | $337.34M | $46.59B |
| Revenue growth (YoY) | +19.3% | +13.0% |
| Gross margin | 64.2% | 56.6% |
| Operating margin | -33.9% | 15.8% |
| Net margin | -32.5% | 11.6% |
| Free cash flow (TTM) | $-84.93M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 98.2% | 81.2% |
| Insider activity (12mo) | 34 buy / 11 sell | 36 buy / 12 sell |
| Short interest (% of float) | 13.0% | 1.1% |
| Analyst consensus | 36% buy / 55% hold / 9% sell (11) | 100% buy (14) |
| Analyst price target | $23 (+32%) | $125 (+28%) |
| StockVane view | ||
| StockVane Quant Rating | D (51) | E (15) |
| Company | ||
| Employees | 888 | 115,000 |
| Founded | 2007 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.